Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
The following information was reported to gore: on march 22, 2024, a gore® viabahn® endoprosthesis (vsx device) was intended for use in the arm during treatment of a clotted graft (artegraft® collagen vascular graft).After the device was advanced through the introducer sheath (manufacturer unknown) over a 0.018" platinum plus guide wire, the physician attempted to deploy the device.However, the zipper bound at the turn around and was unable achieve any device expansion.After a few attempts and no device expansion the physician removed the vsx device through the introducer sheath.An additional vsx device was successfully deployed to complete the procedure.The patient did not experience any adverse consequences.
|